MX2020006125A - Uso de un anticuerpo biespecifico de cea cd3 y un antagonista de la union al eje de pd-1 en un regimen de dosificacion para tratar el cancer. - Google Patents
Uso de un anticuerpo biespecifico de cea cd3 y un antagonista de la union al eje de pd-1 en un regimen de dosificacion para tratar el cancer.Info
- Publication number
- MX2020006125A MX2020006125A MX2020006125A MX2020006125A MX2020006125A MX 2020006125 A MX2020006125 A MX 2020006125A MX 2020006125 A MX2020006125 A MX 2020006125A MX 2020006125 A MX2020006125 A MX 2020006125A MX 2020006125 A MX2020006125 A MX 2020006125A
- Authority
- MX
- Mexico
- Prior art keywords
- cea
- bispecific antibody
- binding antagonist
- axis binding
- treat cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente invención se relaciona con el tratamiento del cáncer, en particular para el tratamiento del cáncer utilizando un anticuerpo biespecífico de CEA CD3 y un antagonista de la unión al eje de PD-1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17207423 | 2017-12-14 | ||
EP18160044 | 2018-03-05 | ||
PCT/EP2018/084652 WO2019115659A1 (en) | 2017-12-14 | 2018-12-13 | Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006125A true MX2020006125A (es) | 2020-08-24 |
Family
ID=64607022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006125A MX2020006125A (es) | 2017-12-14 | 2018-12-13 | Uso de un anticuerpo biespecifico de cea cd3 y un antagonista de la union al eje de pd-1 en un regimen de dosificacion para tratar el cancer. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200407450A1 (es) |
EP (1) | EP3723799A1 (es) |
JP (1) | JP2021506817A (es) |
KR (1) | KR20200099135A (es) |
CN (1) | CN111212660A (es) |
AU (1) | AU2018382966A1 (es) |
CA (1) | CA3079039A1 (es) |
IL (1) | IL275225A (es) |
MX (1) | MX2020006125A (es) |
TW (1) | TW201934578A (es) |
WO (1) | WO2019115659A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3862365A1 (en) * | 2016-01-08 | 2021-08-11 | F. Hoffmann-La Roche AG | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
NZ568769A (en) | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
AR042485A1 (es) | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
SG179204A1 (en) | 2009-10-27 | 2012-04-27 | Micromet Ag | Dosage regimen for administering a cd19xcd3 bispecific antibody |
EP2961771B1 (en) | 2013-02-26 | 2020-01-01 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules specific to cd3 and cea |
WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
AU2015350075B2 (en) | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
SI3789402T1 (sl) * | 2014-11-20 | 2022-10-28 | F. Hoffmann-La Roche Ag | Kombinirano zdravljenje z bispecifičnimi molekulami, ki vežejo antigen in aktivirajo celice T, ter antagonisti za vezavo osi PD-1 |
AU2016368469B2 (en) * | 2015-12-09 | 2023-11-02 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody for reducing formation of anti-drug antibodies |
EP3862365A1 (en) * | 2016-01-08 | 2021-08-11 | F. Hoffmann-La Roche AG | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
CA3042435A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
-
2018
- 2018-12-13 CN CN201880066731.2A patent/CN111212660A/zh active Pending
- 2018-12-13 MX MX2020006125A patent/MX2020006125A/es unknown
- 2018-12-13 EP EP18814941.3A patent/EP3723799A1/en active Pending
- 2018-12-13 KR KR1020207015873A patent/KR20200099135A/ko unknown
- 2018-12-13 CA CA3079039A patent/CA3079039A1/en active Pending
- 2018-12-13 WO PCT/EP2018/084652 patent/WO2019115659A1/en unknown
- 2018-12-13 JP JP2020532892A patent/JP2021506817A/ja active Pending
- 2018-12-13 AU AU2018382966A patent/AU2018382966A1/en active Pending
- 2018-12-13 TW TW107145062A patent/TW201934578A/zh unknown
-
2020
- 2020-06-08 IL IL275225A patent/IL275225A/en unknown
- 2020-06-10 US US16/898,248 patent/US20200407450A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200407450A1 (en) | 2020-12-31 |
EP3723799A1 (en) | 2020-10-21 |
JP2021506817A (ja) | 2021-02-22 |
IL275225A (en) | 2020-07-30 |
KR20200099135A (ko) | 2020-08-21 |
WO2019115659A1 (en) | 2019-06-20 |
AU2018382966A1 (en) | 2020-04-09 |
TW201934578A (zh) | 2019-09-01 |
CN111212660A (zh) | 2020-05-29 |
CA3079039A1 (en) | 2019-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551932A1 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
MY192999A (en) | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
PH12020500075A1 (en) | Checkpoint inhibitor bispecific antibodies | |
MX2022008184A (es) | Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer. | |
MX2017004526A (es) | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. | |
MX2022001757A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. | |
BR112018011029A2 (pt) | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits | |
MX2017005553A (es) | Terapia de combinacion para cancer. | |
MX2018014435A (es) | Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer. | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
PH12019502313A1 (en) | Anti-pd-l1-anti-tim-3 bispecific antibodies | |
MX2017007097A (es) | Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). | |
MX2020003361A (es) | Combinacion de un inhibidor parp y un antagonista de union al eje pd-1. | |
WO2018009507A8 (en) | COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
MX2020006125A (es) | Uso de un anticuerpo biespecifico de cea cd3 y un antagonista de la union al eje de pd-1 en un regimen de dosificacion para tratar el cancer. | |
ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
MX2022005238A (es) | Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida. |